Progress in diagnosis and treatment of heart failure in children
10.3760/cma.j.issn.2095-428X.2020.01.005
- VernacularTitle: 儿童心力衰竭的诊断与治疗进展
- Author:
Mingyang QIAN
1
;
Dian HONG
Author Information
1. Department of Pediatric Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People′s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510000, China
- Publication Type:Journal Article
- Keywords:
Heart failure;
Congenital heart disease;
Pediatric intensive care;
Progress
- From:
Chinese Journal of Applied Clinical Pediatrics
2020;35(1):14-18
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure is a complex clinical syndrome characterized by the heart losing the function of effective blood-pumping and venous return, which will cause a series of symptoms, and its clinical manifestations vary with the age of children.The main causes of heart failure in children are congenital heart disease and cardiomyopathy.Drug therapy for heart failure in children has gained rapid progression recently with Sacubitril/valsartan being a typical one, which was approved by Food and Drug Administration (FDA) in October 2019 for its effective use in symptomatic left ventricular dysfunction in children aged 1 year and above, marking that the drug therapy for heart failure in children stands at a new starting point.Implantable cardioverter defibrillator and cardiac resynchronization therapy are applicable to some patients with indications.Mechanical circulatory support is essential in the treatment of patients with cardiopulmonary failure, including extracorporeal membrane oxygenation and ventricular assist device, which is used as an important transition of short-term circulatory assisted transplantation.Pediatric heart transplantation is a treatment option for end-stage heart failure.
